University of California San Francisco

Makda Zewde
Makda Zewde, MD, MS

Resident (PGY-2) 
General Surgery

    Education

    Institution Degree Dept or School End Date
    Icahn School of Medicine at Mount Sinai MD Doctor of Medicine 05/2023
    Northwestern University MS Biostatistics 06/2019
    Ithaca College BS Biology 05/2015

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 17
    1. Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells.
      Kato T, Matsuda T, Ikeda Y, Park JH, Leisegang M, Yoshimura S, Hikichi T, Harada M, Zewde M, Sato S, Hasegawa K, Kiyotani K, Nakamura Y| | PubMed
    2. Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
      Saloura V, Fatima A, Zewde M, Kiyotani K, Brisson R, Park JH, Ikeda Y, Vougiouklakis T, Bao R, Khattri A, Seiwert T, Cipriani N, Lingen M, Vokes E, Nakamura Y| | PubMed
    3. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
      Park JH, Inoue H, Kato T, Zewde M, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y| | PubMed
    4. WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.
      Saloura V, Vougiouklakis T, Zewde M, Deng X, Kiyotani K, Park JH, Matsuo Y, Lingen M, Suzuki T, Dohmae N, Hamamoto R, Nakamura Y| | PubMed
    5. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.
      Kiyotani K, Park JH, Inoue H, Husain A, Olugbile S, Zewde M, Nakamura Y, Vigneswaran WT| | PubMed
    6. WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.
      Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park JH, Gao G, Karrison T, Lingen M, Nakamura Y, Hamamoto R| | PubMed
    7. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.
      Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y| | PubMed